Skip to main content

Meet the Passionate
Individuals Behind Neurelis

Craig C. Chambliss

President and CEO/Co-Founder

C raig Chambliss has 25 years invested in the pharmaceutical, biotechnology, and drug delivery arenas, with primary focus on diseases of the central nervous system (CNS) and epilepsy, in particular. He co-founded Neurelis in 2007 and has served as CEO and President since 2013. 
In 2010, Mr. Chambliss joined NextWave Pharmaceuticals as Chief Business Officer and directed the corporate refocus to the CNS market, raising $45M in Series C financing and culminating in the sale of NextWave to Pfizer for over $700M in 2012. Prior to NextWave and Neurelis, he led commercial operations at Questcor Pharmaceuticals, from 2005-2007, where he was responsible for helping to engineer the transition to a CNS-focused company and establish the commercial infrastructure to support the relaunch of Acthar® Gel (repository corticotropin injection). 
Mr. Chambliss began his career in pharmaceutical sales at Bristol-Myers Squibb and joined Alza Pharmaceuticals upon the launch of their commercial organization in 1994. While at Alza Pharmaceuticals, he served in various sales and marketing roles prior to joining Elan Pharmaceuticals where he served as Director of Business Development for CNS assets. In 2001, along with other former Dura and Elan executives, Mr. Chambliss launched Xcel Pharmaceuticals, a CNS start-up focused on epilepsy and, primarily, the treatment of acute repetitive seizures. He led commercial operations and the successful launch of Diastat® (diazepam rectal gel) until Xcel's acquisition by Valeant Pharmaceuticals in 2005 for $280M. Mr. Chambliss holds a BS in Finance and a BS in Accounting from Missouri State University.

George Stuart

Chief Financial Officer

G eorge Stuart has 29 years of finance and accounting experience, the majority of which have been spent within the specialty pharmaceutical and biotechnology industry. He has experience as a finance executive with both private and public companies, providing finance-related consulting services to early-stage specialty pharmaceutical and biotech companies. Prior to his involvement with Neurelis in 2010, George spent 3 years as the Senior Vice President and Chief Financial Officer of Questcor Pharmaceuticals where he led the move of Questcor's listing from the American to the NASDAQ exchange. In 2001, he helped launch Xcel Pharmaceuticals, a CNS start-up focused on epilepsy, serving as Vice President and Chief Financial Officer until its acquisition by Valeant Pharmaceuticals in 2005. Prior to the founding of Xcel, George was the Director of Finance for Ligand Pharmaceuticals and began his career with Deloitte in 1986 where he last held the position of Senior Manager.

Chuck DeWildt

Chief Commercial Officer

C huck DeWildt has served in leadership roles in Sales, Marketing, and Market Access in the pharmaceutical and biotechnology industry for more than 25 years. Chuck joined Neurelis initially as Sr. Vice President of Commercial and Market Access in early 2018 and has overseen the commercial buildout of Neurelis since joining. Chuck was promoted to Chief Commercial Officer in 2019. His specific experience includes work in the CNS, respiratory, and oncology markets. Chuck joined Neurelis from Teva Pharmaceuticals Industries Ltd, where he was Vice President of Market Access. He joined Teva in 2011 as part of the Cephalon acquisition where he was the Head of Market Access and Reimbursement. Chuck began his pharmaceutical career at DuPont and joined Cephalon in 1999.

Adrian Rabinowicz, M.D.

Senior Vice President of Clinical Development & Medical Affairs

D  r. Adrian L. Rabinowicz joined Neurelis in 2018 and is a board-certified neurologist with over 20 years of experience in global pharmaceutical and biotechnology companies. Prior to joining Neurelis, he served as Chief Medical Officer at Sancilio & Company, where he led all development programs, operational activities, and interactions with regulatory authorities. Previously, Dr. Rabinowicz was Senior Vice President of Clinical Development and Medical Affairs at Acorda Therapeutics, and also spent over seven years with Bayer HealthCare Pharmaceuticals, holding various roles of increasing responsibility in different therapeutic areas. Dr. Rabinowicz received his medical degree from the Universidad Del Salvador, Buenos Aires, Argentina and completed his residency in neurology at the University of Buenos Aires and his fellowship in Epilepsy and Neurophysiology at the University of Southern California, Los Angeles. He served as both an Assistant Professor of Neurology and the Co-Director of the USC Comprehensive Epilepsy program. Dr. Rabinowicz has received several national and international awards for his research, is a Fellow of the American Academy of Neurology, and has published over 75 peer-reviewed papers and several book chapters.

Thomas Liquard

Senior Vice President, Corporate Development

T homas Liquard brings more than 15 years of organizational, corporate development, and commercial development leadership experience in the life sciences industry to Neurelis. Prior to joining Neurelis in late 2017, Thomas served as CEO of Immuron Limited and was COO and then CEO of Alchemia Limited after spending seven years with Pfizer. At Pfizer, he held various commercial roles of increasing scope and responsibility including in New Product Planning, Portfolio Decision & Analysis, U.S. Established Brands and Emerging Markets. Thomas began his life sciences career as a Senior Consultant with the Frankel Group (now part of the Huron Group). 

Steve Jenner

Vice President of Marketing & Operations

S teve Jenner has more than 20 years of experience in the pharmaceutical and biotechnology industry with specific experience in the neurology, pain, glaucoma, and dermatology markets. Steve joined the Neurelis team in early 2019. He has served in various leadership roles in Sales, Marketing, Operations, and Managed Markets. Steve joined Neurelis from Zogenix, where he most recently served as the Vice President of Commercial for the U.S. Market. At Zogenix, he was responsible for leading the commercialization of multiple product launches, acting as commercial point person for all business development initiatives, and for the initial buildout of the rare disease business unit for the U.S. Market. Prior to Zogenix, he served as the Senior Vice President of Client Services at MedAccess Communications, and held marketing and product management leadership positions with companies such as Valeant Pharmaceuticals International, Allergan Pharmaceuticals, and Elan Pharmaceuticals, Inc. (which was acquired by Alkermes Plc.).

All trademarks are the property of their respective owners.